Efficacy and Safety of Filgotinib for the Treatment of Perianal Fistulising Crohn's Disease [DIVERGENCE 2]: A Phase 2, Randomised, Placebo-controlled Trial.

Walter ReinischJean-Frederic ColombelGeert R A M D'HaensJordi RimolaTomasz MasiorMatt McKevittXuehan RenAdrian SeroneDavid A SchwartzKrisztina B Gecse

Published in: Journal of Crohn's & colitis (2024)

Filgotinib 200 mg was associated with numerical reductions in the number of draining perianal fistulas based on combined clinical and MRI findings compared with placebo, and was generally well tolerated [NCT03077412].

Keyphrases

double blind
clinical trial
placebo controlled
study protocol
magnetic resonance imaging
open label
contrast enhanced
hidradenitis suppurativa
phase iii
randomized controlled trial
diffusion weighted imaging
replacement therapy